Article · 2016
Editor
Paul A. Lapchak
Department of Neurology Davis Research Building D-2091, Director of Translational Research Cedars-Sinai Medical Center, USA
About
As published by the journal they serve.
Dr. Paul A. Lapchak has received his PhD in Pharmacology in 1988 from McGill University (Montreal, Quebec). Currently, he is the Director of Translational Research at Cedars-Sinai Medical Center in Los Angeles, CA. Prior to joining Cedars-Sinai Medical Center, while at the University of California, Dr. Lapchak advanced 2 embolic stroke models to develop new stroke treatments. He is currently serving as an editorial member of Translational Stroke Research and is an active reviewer for STROKE, Experimental Neurology, Brain Research, amongst others. He has authored over 100 peer-reviewed research articles, over 40 review articles and is currently co-editing a new book entitled Translational Stroke Research: From target selection to clinical trials. He is a member of American Heart Association and the Society For Neuroscience. He has been honored as a Fellow of the American Heart Organization (FAHA) for his dedication to the translational development of novel methods to treat acute ischemic stroke and hemorrhagic stroke and has also received a Chemical Industry Award honor.
Journals they serve
The seats these journals name them in.
Articles we hold
Articles in the journals they serve whose byline carries this name.
Article · 2016
JNN Editor's Note
Article · 2015
Neuronal Dysregulation in Stroke-Associated Pseudobulbar Affect (PBA): Diagnostic Scales and Current Treatment Options
Article · 2014
4-((1E)-2-(5-(4-hydroxy-3-methoxystyryl-)-1-phenyl-1H-pyrazoyl-3-yl) vinyl)-2-methoxy-phenol) (CNB-001) Does Not Regulate Human Recombinant Protein-Tyrosine Phosphatase1B (PTP1B) Activity in vitro
Article · 2014
Effect of the Pleiotropic Drug CNB-001 on Tissue Plasminogen Activator (tPA) Protease Activity in vitro: Support for Combination Therapy to Treat Acute Ischemic Stroke
Article · 2013
J-147 a Novel Hydrazide Lead Compound to Treat Neurodegeneration: CeeTox™ Safety and Genotoxicity Analysis
Article · 2013
Synergistic Effect of AJW200, a von Willebrand Factor Neutralizing Antibody with Low Dose (0.9 mg/mg) Thrombolytic Therapy Following Embolic Stroke in Rabbits
Article · 2012
Scientific Rigor Recommendations for Optimizing the Clinical Applicability of Translational Research
Article · 2011
Vascular Dysfunction in Brain Hemorrhage: Translational Pathways to Developing New Treatments from Old Targets
This page holds what the journals publish about this profile: no contact details, and nothing gathered from anywhere else. Ask us to correct or remove this profile.
